Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy and Safety of Benralizumab, a Monoclonal Antibody Against Il-5Rα, in Uncontrolled Eosinophilic Asthma Publisher Pubmed



Khorasanizadeh M1 ; Eskian M1 ; Assaad AH2 ; Rezaei N1, 4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Division of Allergy and Immunology, Cincinnati Children's Medical Center, Cincinnati, OH, United States
  3. 3. Department of Emergency Medicine and Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
  4. 4. Molecular Immunology Research Center, and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: International Reviews of Immunology Published:2016


Abstract

Nonresponders to maximal guideline-based therapies of asthma account for most of the morbidity, mortality, and economic burden of the disease. Because eosinophils are key effector cells in asthmatic airway inflammation, blocking IL-5, the main cytokine responsible for its survival and activation, seems to be a rational strategy. While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise. Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function. In this article, we review the theoretical advantages of benralizumab compared to previous compounds, as well as current status of the clinical development of benralizumab in asthma. Lastly, we briefly discuss the potential role of benralizumab in chronic obstructive pulmonary disease. © 2016, Copyright © Taylor & Francis Group, LLC.
Related Docs
1. Approach to Patients With Severe Asthma: A Consensus Statement From the Respiratory Care Experts’ Input Forum (Rc-Eif), Iran, Tanaffos (2015)
2. Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma, Acta Medica Iranica (2017)
3. Interleukin 9 Serum Level and Single Nucleotide Polymorphism in Patients With Asthma, Acta Biomedica (2021)
4. Immunology of Chronic Obstructive Pulmonary Disease and Sulfur Mustard Induced Airway Injuries: Implications for Immunotherapeutic Interventions, Current Pharmaceutical Design (2016)
5. Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis, Clinical Reviews in Allergy and Immunology (2018)
6. Conjugated Alpha-Alumina Nanoparticle With Vasoactive Intestinal Peptide As a Nano-Drug in Treatment of Allergic Asthma in Mice, European Journal of Pharmacology (2016)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (3)
Zahra Pourpak (1)